ARMP insider transaction filings
Armata Pharmaceuticals, Inc. — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-14. Screen ARMP transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Birx Deborah — Chief Executive Officer, Director | 1 | — | — | 1 |
Recent Form 4 filings — Armata Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-14 | 4 | Birx Deborah — Chief Executive Officer, Director | Tax withholding (F): 14,041 @ $4.26 | EDGAR |
| 2026-04-28 | 4 | Gilmer Daniel B. — Director | Grant/award (A): 51,280 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Kyme Pierre — Chief Business Officer | Tax withholding (F): 1,030 @ $10.54 | EDGAR |
| 2026-03-17 | 4 | Birx Deborah — Chief Executive Officer, Director | Tax withholding (F): 4,919 @ $10.54 | EDGAR |
| 2026-03-11 | 4 | House David Duane — SVP, Finance, and PFO | Grant/award (A): 109,885 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Kyme Pierre — Chief Business Officer | Grant/award (A): 183,142 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Birx Deborah — Chief Executive Officer, Director | Grant/award (A): 421,226 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Peterson Todd C. — Director | Grant/award (A): 25,640 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Kramer Robin — Director | Grant/award (A): 25,640 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Schlesinger Sarah J. — Director | Grant/award (A): 25,640 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Odysseas Kostas D — Director | Grant/award (A): 25,640 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Haimovitz Jules — Director | Grant/award (A): 25,640 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | PATTI JOSEPH M — Director | Grant/award (A): 25,640 (derivative) @ $0 | EDGAR |
| 2025-07-14 | 4 | Birx Deborah — Chief Executive Officer, Director | Tax withholding (F): 13,637 @ $2.27 | EDGAR |
| 2025-04-25 | 4 | Kyme Pierre — Chief Business Officer | Tax withholding (F): 1,027 @ $1.95 | EDGAR |
| 2025-04-25 | 4 | Birx Deborah — Chief Executive Officer, Director | Tax withholding (F): 22,925 @ $2.68 · Tax withholding (F): 6,061 @ $1.95 | EDGAR |
| 2025-02-07 | 4 | House David Duane — SVP, Finance, and PFO | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Kyme Pierre — Chief Business Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Birx Deborah — Chief Executive Officer, Director | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Peterson Todd C. — Director | Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Kramer Robin — Director | Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Schlesinger Sarah J. — Director | Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Odysseas Kostas D — Director | Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Haimovitz Jules — Director | Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | PATTI JOSEPH M — Director | Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | House David Duane — SVP, Finance, and PFO | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Rychlik Richard — Corporate Controller and PFO | Grant/award (A): 10,000 @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Birx Deborah — Chief Executive Officer, Director | Grant/award (A): 60,000 @ $0 · Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Peterson Todd C. — Director | Grant/award (A): 39,666 (derivative) @ $0 · Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Kramer Robin — Director | Grant/award (A): 39,666 (derivative) @ $0 · Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Schlesinger Sarah J. — Director | Grant/award (A): 39,666 (derivative) @ $0 · Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Odysseas Kostas D — Director | Grant/award (A): 39,666 (derivative) @ $0 · Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Haimovitz Jules — Director | Grant/award (A): 39,666 (derivative) @ $0 · Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | PATTI JOSEPH M — Director | Grant/award (A): 39,666 (derivative) @ $0 · Grant/award (A): 54,343 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Rychlik Richard — Corporate Controller and PFO | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Birx Deborah — Chief Executive Officer, Director | Grant/award (A): 200,000 @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Peterson Todd C. — Director | Grant/award (A): 10,461 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Kramer Robin — Director | Grant/award (A): 10,461 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Schlesinger Sarah J. — Director | Grant/award (A): 10,461 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Odysseas Kostas D — Director | Grant/award (A): 10,461 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Haimovitz Jules — Director | Grant/award (A): 10,461 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | PATTI JOSEPH M — Director | Grant/award (A): 10,461 (derivative) @ $0 | EDGAR |
Recent 8-K events — Armata Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ARMP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →